Literature DB >> 1531782

Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1.

T H Inge1, S K Hoover, B M Susskind, S K Barrett, H D Bear.   

Abstract

Transforming growth factor beta (TGF-beta) is a potent immunosuppressive cytokine that is produced by neoplastic and normal cells. It has not been demonstrated directly, however, that TGF-beta can inhibit antigen-specific T-cell responses to tumor cells in vitro. We show here that generation of antitumor cytotoxic T-lymphocyte (CTL) activity in mixed-lymphocyte tumor cultures of splenocytes from DBA/2 mice immunized with the syngeneic P815 mastocytoma + Corynebacterium parvum was consistently and profoundly inhibited when 0.675 to 10 ng/ml of TGF-beta were added on Day 0 of culture. TGF-beta added on Day 1 or later had little or no effect. In contrast to the results with P815 immune mice, mixed-lymphocyte tumor cultures established with splenocytes from P815 tumor-bearing hosts showed variable degrees of inhibition by TGF-beta, depending on the stage of the ongoing in vivo immune response. Addition of recombinant murine tumor necrosis factor alpha (1,000 or 10,000 units/ml) partially reversed inhibition of CTL responses by TGF-beta, while recombinant interleukin 2 nearly completely reversed the suppression. These data indicate that one level at which TGF-beta may act to inhibit mixed-lymphocyte tumor cultures is that of cytokine production. To determine whether TGF-beta also has any direct effect on CTL, P815-specific CTL clones derived from tumor-bearing host mice were utilized. We found that proliferation of rested CTL clones in response to tumor cells + interleukin 2 was inhibited by 5 ng/ml of TGF-beta, while the interleukin 2-dependent reactivation of cytolytic activity was not affected by TGF-beta. In contrast to rested CTL, when TGF-beta was added to cultures of previously activated CTL, proliferation was not inhibited. These data demonstrate that TGF-beta has profound inhibitory effects on the in vitro generation of effector CTL from tumor-specific murine splenocytes, and this inhibition may be an indirect result of suppressed cytokine production as well as a direct antiproliferative effect on CTL.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1531782

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  4-1BB regulates NKG2D costimulation in human cord blood CD8+ T cells.

Authors:  Young-June Kim; Myung-Kwan Han; Hal E Broxmeyer
Journal:  Blood       Date:  2007-11-16       Impact factor: 22.113

2.  Failure of tumor-reactive lymph node cells to kill tumor in the presence of immune-suppressive CD34+ cells can be overcome with vitamin D3 treatment to diminish CD34+ cell levels.

Authors:  K Wiers; M A Wright; K Vellody; M R Young
Journal:  Clin Exp Metastasis       Date:  1998-04       Impact factor: 5.150

3.  Scutellaria extract and wogonin inhibit tumor-mediated induction of T(reg) cells via inhibition of TGF-β1 activity.

Authors:  Sagar Dandawate; Linford Williams; Nirmal Joshee; Agnes M Rimando; Sandeep Mittal; Archana Thakur; Lawrence G Lum; Prahlad Parajuli
Journal:  Cancer Immunol Immunother       Date:  2011-11-06       Impact factor: 6.968

4.  Neutralization of transforming growth factor beta 1 augments hepatitis C virus-specific cytotoxic T lymphocyte induction in vitro.

Authors:  T Kanto; T Takehara; K Katayama; A Ito; K Mochizuki; N Kuzushita; T Tatsumi; Y Sasaki; A Kasahara; N Hayashi; M Hori
Journal:  J Clin Immunol       Date:  1997-11       Impact factor: 8.317

5.  Transforming growth factor-beta 1 enhances the generation of allospecific cytotoxic T lymphocytes.

Authors:  S Kondo; K Isobe; N Ishiguro; I Nakashima; T Miura
Journal:  Immunology       Date:  1993-07       Impact factor: 7.397

6.  Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy.

Authors:  L M Weiskirch; Y Bar-Dagan; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

Review 7.  New aspects of immunotherapy of leptomeningeal metastasis.

Authors:  U Herrlinger; M Weller; M Schabet
Journal:  J Neurooncol       Date:  1998 Jun-Jul       Impact factor: 4.130

8.  Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients.

Authors:  A Boiardi; A Silvani; P A Ruffini; L Rivoltini; G Parmiani; G Broggi; A Salmaggi
Journal:  Cancer Immunol Immunother       Date:  1994-09       Impact factor: 6.968

9.  Human lung tumor cell secretion of interleukin-2 for protection against tumor engraftment.

Authors:  T Alosco; B Gansbacher; R Bankert; H Takita; N Petrelli
Journal:  Ann Surg Oncol       Date:  1994-05       Impact factor: 5.344

Review 10.  Transforming growth factor-beta and its implication in the malignancy of gliomas.

Authors:  Laurent-Olivier Roy; Marie-Belle Poirier; David Fortin
Journal:  Target Oncol       Date:  2014-03-05       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.